ANIK — Anika Therapeutics Balance Sheet
0.000.00%
Last trade - 00:00HealthcareBalancedSmall CapNeutral
- $420.26m
- $333.93m
- $156.24m
- 92
- 46
- 70
- 79
Annual balance sheet for Anika Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2018 December 31st | 2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Cash and Equivalents | |||||
| Short Term Investments | |||||
| Cash and Short Term Investments | 159 | 185 | 98.3 | 94.4 | 86.3 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 20.8 | 23.1 | 24.1 | 29.8 | 34.6 |
| Total Inventory | |||||
| Prepaid Expenses | |||||
| Total Current Assets | 203 | 234 | 177 | 169 | 170 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 54.1 | 73.6 | 73.2 | 68.6 | 79 |
| Net Goodwill | |||||
| Net Intangible Assets | |||||
| Other Long Term Assets | |||||
| Total Assets | 279 | 331 | 366 | 348 | 349 |
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 11.3 | 16.3 | 36.9 | 29.8 | 27.9 |
| Total Long Term Debt | |||||
| Total Debt | |||||
| Deferred Income Tax | |||||
| Total Other Liabilities | |||||
| Total Liabilities | 15.4 | 42.3 | 93.2 | 60.5 | 63.6 |
| Non Redeemable Preferred Stock | |||||
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Other Equity | |||||
| Total Equity | 264 | 288 | 272 | 287 | 286 |
| Total Liabilities & Shareholders' Equity | 279 | 331 | 366 | 348 | 349 |
| Total Common Shares Outstanding |